BACKGROUND AND PURPOSE: We have previously demonstrated that the local delivery of monocyte chemotactic protein-1 (MCP-1) via an MCP-1-releasing poly(lactic-co-glycolic acid)-coated coil promotes intra-aneurysmal tissue healing. In this study, we demonstrate that interleukin-6 (IL-6) and osteopontin are downstream mediators in the MCP-1-mediated aneurysm-healing pathway. METHODS: Murine carotid aneurysms were created in C57BL/6 mice. Drug-releasing coils (MCP-1, IL-6, and osteopontin) and control poly(lactic-co-glycolic acid) coils were created and then implanted into the aneurysms to evaluate their intra-aneurismal-healing capacity. To investigate the downstream mediators for aneurysm healing, blocking antibodies for IL-6 receptor and osteopontin were given to the mice implanted with the MCP-1-releasing coils. A histological analysis of both murine and human aneurysms was utilized to cross-validate the data. RESULTS: We observed increased expression of IL-6 in MCP-1-coil-treated aneurysms and not in control-poly(lactic-co-glycolic acid)-only-treated aneurysms. MCP-1-mediated intra-aneurysmal healing is inhibited in mice given blocking antibody to IL-6 receptor. MCP-1-mediated intra-aneurysmal healing is also inhibited by blocking antibody to osteopontin. The role of IL-6 in intra-aneurysmal healing is in recruiting of endothelial cells and fibroblasts. Local delivery of osteopontin to murine carotid aneurysms via osteopontin-releasing coil significantly promotes intra-aneurysmal healing, but IL-6-releasing coil does not, suggesting that IL-6 cannot promote aneurysm healing independent of MCP-1. In the MCP-1-mediated aneurysm healing, osteopontin expression is dependent on IL-6; inhibition of IL-6 receptor significantly inhibits osteopontin expression in MCP-1-mediated aneurysm healing. CONCLUSIONS: Our findings suggest that IL-6 and osteopontin are key downstream mediators of MCP-1-mediated intra-aneurysmal healing.
BACKGROUND AND PURPOSE: We have previously demonstrated that the local delivery of monocyte chemotactic protein-1 (MCP-1) via an MCP-1-releasing poly(lactic-co-glycolic acid)-coated coil promotes intra-aneurysmal tissue healing. In this study, we demonstrate that interleukin-6 (IL-6) and osteopontin are downstream mediators in the MCP-1-mediated aneurysm-healing pathway. METHODS:Murinecarotid aneurysms were created in C57BL/6 mice. Drug-releasing coils (MCP-1, IL-6, and osteopontin) and control poly(lactic-co-glycolic acid) coils were created and then implanted into the aneurysms to evaluate their intra-aneurismal-healing capacity. To investigate the downstream mediators for aneurysm healing, blocking antibodies for IL-6 receptor and osteopontin were given to the mice implanted with the MCP-1-releasing coils. A histological analysis of both murine and humananeurysms was utilized to cross-validate the data. RESULTS: We observed increased expression of IL-6 in MCP-1-coil-treated aneurysms and not in control-poly(lactic-co-glycolic acid)-only-treated aneurysms. MCP-1-mediated intra-aneurysmal healing is inhibited in mice given blocking antibody to IL-6 receptor. MCP-1-mediated intra-aneurysmal healing is also inhibited by blocking antibody to osteopontin. The role of IL-6 in intra-aneurysmal healing is in recruiting of endothelial cells and fibroblasts. Local delivery of osteopontin to murinecarotid aneurysms via osteopontin-releasing coil significantly promotes intra-aneurysmal healing, but IL-6-releasing coil does not, suggesting that IL-6 cannot promote aneurysm healing independent of MCP-1. In the MCP-1-mediated aneurysm healing, osteopontin expression is dependent on IL-6; inhibition of IL-6 receptor significantly inhibits osteopontin expression in MCP-1-mediated aneurysm healing. CONCLUSIONS: Our findings suggest that IL-6 and osteopontin are key downstream mediators of MCP-1-mediated intra-aneurysmal healing.
Authors: Brian L Hoh; Koji Hosaka; Daniel P Downes; Kamil W Nowicki; Cristina E Fernandez; Christopher D Batich; Edward W Scott Journal: Circulation Date: 2011-10-17 Impact factor: 29.690
Authors: R M Gallucci; T Sugawara; B Yucesoy; K Berryann; P P Simeonova; J M Matheson; M I Luster Journal: J Interferon Cytokine Res Date: 2001-08 Impact factor: 2.607
Authors: B K Arendt; A Velazquez-Dones; R C Tschumper; K G Howell; S M Ansell; T E Witzig; D F Jelinek Journal: Leukemia Date: 2002-10 Impact factor: 11.528
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Brian L Hoh; Hanain Z Fazal; Siham Hourani; Mengchen Li; Li Lin; Koji Hosaka Journal: J Neurointerv Surg Date: 2017-04-27 Impact factor: 5.836
Authors: Sarah M Chau; Scott M Herting; Dillon A Noltensmeyer; Hamzah Ahmed; Duncan J Maitland; Shreya Raghavan Journal: J Biomed Mater Res B Appl Biomater Date: 2022-01-28 Impact factor: 3.405
Authors: Yuek Ling Chai; Joyce R Chong; Ainiah R Raquib; Xin Xu; Saima Hilal; Narayanaswamy Venketasubramanian; Boon Yeow Tan; Alan P Kumar; Gautam Sethi; Christopher P Chen; Mitchell K P Lai Journal: Sci Rep Date: 2021-02-17 Impact factor: 4.379
Authors: Dimitri Laurent; Brandon Lucke-Wold; Owen Leary; Morgan H Randall; Ken Porche; Matthew Koch; Nohra Chalouhi; Adam Polifka; Brian L Hoh Journal: Neurosci Insights Date: 2022-07-30
Authors: Kerry E Poppenberg; Haley R Zebraski; Naval Avasthi; Muhammad Waqas; Adnan H Siddiqui; James N Jarvis; Vincent M Tutino Journal: BMC Med Genomics Date: 2021-06-16 Impact factor: 3.063
Authors: Siham Hourani; Kartik Motwani; Daisuke Wajima; Hanain Fazal; Chad H Jones; Sylvain Doré; Koji Hosaka; Brian L Hoh Journal: Front Neurol Date: 2018-03-19 Impact factor: 4.003
Authors: Muhammad U Sohail; Layla Al-Mansoori; Hend Al-Jaber; Costas Georgakopoulos; Francesco Donati; Francesco Botrè; Maha Sellami; Mohamed A Elrayess Journal: Front Physiol Date: 2020-10-15 Impact factor: 4.566